Sectors & IndustriesHealthcareMedical Instruments & Supplies

Best Medical Stocks to Buy Now (2025)

Top medical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best medical stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical stocks to buy right now are:

Infusystem Holdings (NYSEMKT:INFU) is the #1 top medical stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: B, Momentum: D, Sentiment: A, Safety: C, Financials: B, and AI: C.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 24, which is -4 points lower than the medical industry average of 28. Although this number is below the industry average, our proven quant model rates INFU as a "A".

INFU passed 7 out of 33 due diligence checks and has weak fundamentals. Infusystem Holdings has seen its stock lose -6.9% over the past year, overperforming other medical stocks by 44 percentage points.

Embecta (NASDAQ:EMBC) is the #2 top medical stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: C, Momentum: D, Sentiment: A, Safety: D, Financials: B, and AI: A.

Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 7 points higher than the medical industry average of 28.

EMBC passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -26.8% over the past year, overperforming other medical stocks by 24 percentage points.

Embecta has an average 1 year price target of $13.00, an upside of 35.98% from Embecta's current stock price of $9.56.

Embecta stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Embecta, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Dentsply Sirona (NASDAQ:XRAY) is the #3 top medical stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Dentsply Sirona (NASDAQ:XRAY) is: Value: B, Growth: C, Momentum: D, Sentiment: A, Safety: B, Financials: C, and AI: C.

Dentsply Sirona (NASDAQ:XRAY) has a Due Diligence Score of 28, which is equal to the medical industry average of 28.

XRAY passed 9 out of 38 due diligence checks and has average fundamentals. Dentsply Sirona has seen its stock lose -41.46% over the past year, overperforming other medical stocks by 9 percentage points.

Dentsply Sirona has an average 1 year price target of $20.50, an upside of 31.16% from Dentsply Sirona's current stock price of $15.63.

Dentsply Sirona stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Dentsply Sirona, 20% have issued a Strong Buy rating, 20% have issued a Buy, 60% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 10 medical stocks that have issued dividends in the past year, the 3 medical stocks with the highest dividend yields are:

Embecta (NASDAQ:EMBC) has an annual dividend yield of 4.71%, which is 3 percentage points higher than the medical industry average of 1.77%.

Embecta's dividend payout ratio of 66.7% indicates that its high dividend yield is sustainable for the long-term.

Dentsply Sirona (NASDAQ:XRAY) has an annual dividend yield of 3.07%, which is 1 percentage points higher than the medical industry average of 1.77%. Dentsply Sirona's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Dentsply Sirona's dividend has shown consistent growth over the last 10 years.

Dentsply Sirona's dividend payout ratio of -14.2% indicates that its dividend yield might not be sustainable for the long-term.

Baxter International (NYSE:BAX) has an annual dividend yield of 2.61%, which is 1 percentage points higher than the medical industry average of 1.77%. Baxter International's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Baxter International's dividend has shown consistent growth over the last 10 years.

Baxter International's dividend payout ratio of -83.6% indicates that its dividend yield might not be sustainable for the long-term.

Medical stocks were down -1.39% in the last day, and down -3.05% over the last week.

We couldn't find a catalyst for why medical stocks are down.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued medical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 39 points higher than the medical industry average of 18. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -26.8% in the past year. It has overperformed other stocks in the medical industry by 24 percentage points.

Teleflex (NYSE:TFX) is the second most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Teleflex has a valuation score of 43, which is 25 points higher than the medical industry average of 18. It passed 3 out of 7 valuation due diligence checks.

Teleflex's stock has dropped -42.7% in the past year. It has overperformed other stocks in the medical industry by 8 percentage points.

Haemonetics (NYSE:HAE) is the third most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Haemonetics has a valuation score of 43, which is 25 points higher than the medical industry average of 18. It passed 3 out of 7 valuation due diligence checks.

Haemonetics's stock has dropped -18.55% in the past year. It has overperformed other stocks in the medical industry by 32 percentage points.

43.59% of medical stocks rated by analysts are a strong buy right now. On average, analysts expect medical stocks to rise by 28.91% over the next year.

2.27% of medical stocks have a Zen Rating of A (Strong Buy), 15.91% of medical stocks are rated B (Buy), 65.91% are rated C (Hold), 9.09% are rated D (Sell), and 6.82% are rated F (Strong Sell).